{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:46:27Z","timestamp":1792853187030,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220797\/Z\/20\/Z"],"award-info":[{"award-number":["220797\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Understanding mechanisms of antibody synergy is important for vaccine design and antibody cocktail development. Examples of synergy between antibodies are well-documented, but the mechanisms underlying these relationships often remain poorly understood. The leading blood-stage malaria vaccine candidate, CyRPA, is essential for invasion of\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    into human erythrocytes. Here we present a panel of anti-CyRPA monoclonal antibodies that strongly inhibit parasite growth in in vitro assays. Structural studies show that growth-inhibitory antibodies bind epitopes on a single face of CyRPA. We also show that pairs of non-competing inhibitory antibodies have strongly synergistic growth-inhibitory activity. These antibodies bind to neighbouring epitopes on CyRPA and form lateral, heterotypic interactions which slow antibody dissociation. We predict that such heterotypic interactions will be a feature of many immune responses. Immunogens which elicit such synergistic antibody mixtures could increase the potency of vaccine-elicited responses to provide robust and long-lived immunity against challenging disease targets.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-28601-4","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T06:02:53Z","timestamp":1645077773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Heterotypic interactions drive antibody synergy against a malaria vaccine candidate"],"prefix":"10.1038","volume":"13","author":[{"given":"Robert J.","family":"Ragotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-7761","authenticated-orcid":false,"given":"Amelia M.","family":"Lias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-6452","authenticated-orcid":false,"given":"Doris","family":"Quinkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G. W.","family":"Alanine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Jamwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2917-9062","authenticated-orcid":false,"given":"Hannah","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5326-7935","authenticated-orcid":false,"given":"Ad\u00e9la","family":"Nacer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1757-0208","authenticated-orcid":false,"given":"Edward D.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4957-8175","authenticated-orcid":false,"given":"Geoffrey W.","family":"Grime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Illingworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-5690","authenticated-orcid":false,"given":"Robert F.","family":"Donat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-5665","authenticated-orcid":false,"given":"Elspeth F.","family":"Garman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-9191","authenticated-orcid":false,"given":"Paul W.","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-1955","authenticated-orcid":false,"given":"Matthew K.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-1357","authenticated-orcid":false,"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"28601_CR1","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1128\/jvi.70.7.4466-4473.1996","volume":"70","author":"S Vijh-Warrier","year":"1996","unstructured":"Vijh-Warrier, S., Pinter, A., Honnen, W. J. & Tilley, S. A. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J. Virol. 70, 4466\u20134473 (1996).","journal-title":"J. Virol."},{"key":"28601_CR2","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","volume":"3","author":"J Ter Meulen","year":"2006","unstructured":"Ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med. 3, e237\u2013e237 (2006).","journal-title":"PLoS Med."},{"key":"28601_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"28601_CR4","doi-asserted-by":"publisher","first-page":"E82","DOI":"10.1073\/pnas.1718441115","volume":"115","author":"MC Mankowski","year":"2018","unstructured":"Mankowski, M. C. et al. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proc. Natl Acad. Sci. USA 115, E82\u2013E91 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28601_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2019.05.025","volume":"178","author":"DGW Alanine","year":"2019","unstructured":"Alanine, D. G. W. et al. Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies. Cell 178, 216\u2013228 (2019).","journal-title":"Cell"},{"key":"28601_CR6","doi-asserted-by":"publisher","first-page":"12045","DOI":"10.1073\/pnas.1702944114","volume":"114","author":"LY Bustamante","year":"2017","unstructured":"Bustamante, L. Y. et al. Synergistic malaria vaccine combinations identified by systematic antigen screening. Proc. Natl Acad. Sci. USA 114, 12045\u201312050 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28601_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3389\/fimmu.2019.01254","volume":"10","author":"JJ Illingworth","year":"2019","unstructured":"Illingworth, J. J. et al. Functional comparison of blood-stage Plasmodium falciparum malaria vaccine candidate antigens. Front. Immunol. 10, 1254 (2019).","journal-title":"Front. Immunol."},{"key":"28601_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","volume":"19","author":"KA Howell","year":"2017","unstructured":"Howell, K. A. et al. Cooperativity enables non-neutralizing antibodies to neutralize ebolavirus. Cell Rep. 19, 413\u2013424 (2017).","journal-title":"Cell Rep."},{"key":"28601_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.immuni.2020.01.001","volume":"52","author":"P Gilchuk","year":"2020","unstructured":"Gilchuk, P. et al. Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization. Immunity 52, 388\u2013403 (2020).","journal-title":"Immunity"},{"key":"28601_CR10","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.aar5304","volume":"360","author":"K Imkeller","year":"2018","unstructured":"Imkeller, K. et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 360, 1358\u20131362 (2018).","journal-title":"Science"},{"key":"28601_CR11","doi-asserted-by":"publisher","first-page":"eaau8529","DOI":"10.1126\/sciadv.aau8529","volume":"4","author":"D Oyen","year":"2018","unstructured":"Oyen, D. et al. Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Sci. Adv. 4, eaau8529 (2018).","journal-title":"Sci. Adv."},{"key":"28601_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21221-4","volume":"12","author":"T Pholcharee","year":"2021","unstructured":"Pholcharee, T. et al. Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. Nat. Commun. 12, 1063 (2021).","journal-title":"Nat. Commun."},{"key":"28601_CR13","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.aaz9356","volume":"367","author":"L Roug\u00e9","year":"2020","unstructured":"Roug\u00e9, L. et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science 367, 1224\u20131230 (2020).","journal-title":"Science"},{"key":"28601_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","volume":"24","author":"SJ Draper","year":"2018","unstructured":"Draper, S. J. et al. Malaria vaccines: Recent advances and new horizons. Cell Host Microbe 24, 43\u201356 (2018).","journal-title":"Cell Host Microbe"},{"key":"28601_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.pt.2020.04.003","volume":"36","author":"RJ Ragotte","year":"2020","unstructured":"Ragotte, R. J., Higgins, M. K. & Draper, S. J. The RH5-CyRPA-Ripr complex as a malaria vaccine target. Trends Parasitol. 36, 545\u2013559 (2020).","journal-title":"Trends Parasitol."},{"key":"28601_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1615","volume":"2","author":"AD Douglas","year":"2011","unstructured":"Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2, 601 (2011).","journal-title":"Nat. Commun."},{"key":"28601_CR17","doi-asserted-by":"publisher","first-page":"e1002199","DOI":"10.1371\/journal.ppat.1002199","volume":"7","author":"L Chen","year":"2011","unstructured":"Chen, L. et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog. 7, e1002199 (2011).","journal-title":"PLoS Pathog."},{"key":"28601_CR18","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.4049\/jimmunol.1103177","volume":"188","author":"AM Dreyer","year":"2012","unstructured":"Dreyer, A. M. et al. Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen. J. Immunol. 188, 6225\u20136237 (2012).","journal-title":"J. Immunol."},{"key":"28601_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","volume":"17","author":"AD Douglas","year":"2015","unstructured":"Douglas, A. D. et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in Aotus monkeys. Cell Host Microbe 17, 130\u2013139 (2015).","journal-title":"Cell Host Microbe"},{"key":"28601_CR20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","volume":"2","author":"AM Minassian","year":"2021","unstructured":"Minassian, A. M. et al. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med 2, 701\u2013719 (2021).","journal-title":"Med"},{"key":"28601_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-016-0232-6","volume":"16","author":"G Kivi","year":"2016","unstructured":"Kivi, G. et al. HybriFree: A robust and rapid method for the development of monoclonal antibodies from different host species. BMC Biotechnol. 16, 2 (2016).","journal-title":"BMC Biotechnol."},{"key":"28601_CR22","doi-asserted-by":"publisher","first-page":"e21347","DOI":"10.7554\/eLife.21347","volume":"6","author":"L Chen","year":"2017","unstructured":"Chen, L. et al. Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA. eLife 6, e21347 (2017).","journal-title":"eLife"},{"key":"28601_CR23","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1128\/IAI.73.6.3677-3685.2005","volume":"73","author":"EM Malkin","year":"2005","unstructured":"Malkin, E. M. et al. Phase 1 clinical trial of apical membrane antigen 1: An asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73, 3677\u20133685 (2005).","journal-title":"Infect. Immun."},{"key":"28601_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1073\/pnas.1415466112","volume":"112","author":"KS Reddy","year":"2015","unstructured":"Reddy, K. S. et al. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc. Natl Acad. Sci. USA 112, 1179\u20131184 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28601_CR25","doi-asserted-by":"publisher","first-page":"e13030","DOI":"10.1111\/cmi.13030","volume":"21","author":"J Healer","year":"2019","unstructured":"Healer, J. et al. Neutralizing antibodies block the function of Rh5\/Ripr\/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes. Cell. Microbiol. 21, e13030 (2019).","journal-title":"Cell. Microbiol."},{"key":"28601_CR26","doi-asserted-by":"crossref","unstructured":"Favuzza, P. et al. Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. eLife 6, e20383 (2017).","DOI":"10.7554\/eLife.20383"},{"key":"28601_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1021\/cr020467n","volume":"103","author":"T Dudev","year":"2003","unstructured":"Dudev, T. & Lim, C. Principles governing Mg, Ca, and Zn binding and selectivity in proteins. Chem. Rev. 103, 773\u2013788 (2003).","journal-title":"Chem. Rev."},{"key":"28601_CR28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1107\/S0907444904004081","volume":"60","author":"MM Harding","year":"2004","unstructured":"Harding, M. M. The architecture of metal coordination groups in proteins. Acta Crystallogr. Sect. D 60, 849\u2013859 (2004).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"28601_CR29","doi-asserted-by":"publisher","first-page":"14575","DOI":"10.1073\/pnas.0507267102","volume":"102","author":"T Zhou","year":"2005","unstructured":"Zhou, T., Hamer, D. H., Hendrickson, W. A., Sattentau, Q. J. & Kwong, P. D. Interfacial metal and antibody recognition. Proc. Natl Acad. Sci. USA 102, 14575\u201314580 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"28601_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41586-018-0779-6","volume":"565","author":"W Wong","year":"2019","unstructured":"Wong, W. et al. Structure of Plasmodium falciparum Rh5\u2013CyRPA\u2013Ripr invasion complex. Nature 565, 118\u2013121 (2019).","journal-title":"Nature"},{"key":"28601_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585\u2013615 (1939).","journal-title":"Ann. Appl. Biol."},{"key":"28601_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67877-8","volume":"10","author":"Y Azasi","year":"2020","unstructured":"Azasi, Y. et al. Bliss\u2019 and Loewe\u2019s additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR, and CyRPA antibody combinations. Sci. Rep. 10, 11802 (2020).","journal-title":"Sci. Rep."},{"key":"28601_CR33","doi-asserted-by":"publisher","first-page":"e1002991","DOI":"10.1371\/journal.ppat.1002991","volume":"8","author":"AR Williams","year":"2012","unstructured":"Williams, A. R. et al. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: Assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog. 8, e1002991 (2012).","journal-title":"PLoS Pathog."},{"key":"28601_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4049\/jimmunol.1302045","volume":"192","author":"AD Douglas","year":"2014","unstructured":"Douglas, A. D. et al. Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J. Immunol. 192, 245\u2013258 (2014).","journal-title":"J. Immunol."},{"key":"28601_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1074-7613(00)80580-4","volume":"8","author":"FD Batista","year":"1998","unstructured":"Batista, F. D. & Neuberger, M. S. Affinity dependence of the B cell response to antigen: A threshold, a ceiling, and the importance of off-rate. Immunity 8, 751\u2013759 (1998).","journal-title":"Immunity"},{"key":"28601_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature12966","volume":"507","author":"BE Correia","year":"2014","unstructured":"Correia, B. E. et al. Proof of principle for epitope-focused vaccine design. Nature 507, 201\u2013206 (2014).","journal-title":"Nature"},{"key":"28601_CR37","doi-asserted-by":"publisher","first-page":"eaay5051","DOI":"10.1126\/science.aay5051","volume":"368","author":"F Sesterhenn","year":"2020","unstructured":"Sesterhenn, F. et al. De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science 368, eaay5051 (2020).","journal-title":"Science"},{"key":"28601_CR38","doi-asserted-by":"publisher","first-page":"e0007860","DOI":"10.1371\/journal.pntd.0007860","volume":"14","author":"R Hooft van Huijsduijnen","year":"2020","unstructured":"Hooft van Huijsduijnen, R. et al. Reassessing therapeutic antibodies for neglected and tropical diseases. PLoS Negl. Trop. Dis. 14, e0007860 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"28601_CR39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa2034031","volume":"385","author":"MR Gaudinski","year":"2021","unstructured":"Gaudinski, M. R. et al. A monoclonal antibody for malaria. Prev. N. Engl. J. Med. 385, 803\u2013814 (2021).","journal-title":"Prev. N. Engl. J. Med."},{"key":"28601_CR40","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41591-020-0881-9","volume":"26","author":"R Murugan","year":"2020","unstructured":"Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. 26, 1135\u20131145 (2020).","journal-title":"Nat. Med."},{"key":"28601_CR41","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1016\/j.celrep.2020.02.061","volume":"30","author":"B Nogal","year":"2020","unstructured":"Nogal, B. et al. Mapping polyclonal antibody responses in non-human primates vaccinated with HIV Env trimer subunit vaccines. Cell Rep. 30, 3755\u20133765.e7 (2020).","journal-title":"Cell Rep."},{"key":"28601_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0071-7","volume":"3","author":"J Jin","year":"2018","unstructured":"Jin, J. et al. Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. NPJ Vaccines 3, 32 (2018).","journal-title":"NPJ Vaccines"},{"key":"28601_CR43","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nature06890","volume":"453","author":"J Wrammert","year":"2008","unstructured":"Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667\u2013671 (2008).","journal-title":"Nature"},{"key":"28601_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijpara.2016.12.001","volume":"47","author":"J Jin","year":"2017","unstructured":"Jin, J. et al. Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal \u2018C-tag\u2019. Int. J. Parasitol. 47, 435\u2013446 (2017).","journal-title":"Int. J. Parasitol."},{"key":"28601_CR45","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","volume":"27","author":"P Rijal","year":"2019","unstructured":"Rijal, P. et al. Therapeutic monoclonal antibodies for ebola virus infection derived from vaccinated humans. Cell Rep. 27, 172\u2013186.e7 (2019).","journal-title":"Cell Rep."},{"key":"28601_CR46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0168-583X(94)00540-0","volume":"95","author":"JA Maxwell","year":"1995","unstructured":"Maxwell, J. A., Teesdale, W. J. & Campbell, J. L. The Guelph PIXE software package II. Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At. 95, 407\u2013421 (1995).","journal-title":"Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At."},{"key":"28601_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pbiomolbio.2004.09.005","volume":"89","author":"EF Garman","year":"2005","unstructured":"Garman, E. F. & Grime, G. W. Elemental analysis of proteins by microPIXE. Prog. Biophys. Mol. Biol. 89, 173\u2013205 (2005).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"28601_CR48","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1107\/S0909049509036681","volume":"16","author":"M-F Incardona","year":"2009","unstructured":"Incardona, M.-F. et al. EDNA: A framework for plugin-based applications applied to X-ray experiment online data analysis. J. Synchrotron. Radiat. 16, 872\u2013879 (2009).","journal-title":"J. Synchrotron. Radiat."},{"key":"28601_CR49","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1107\/S0907444999009506","volume":"55","author":"HR Powell","year":"1999","unstructured":"Powell, H. R. The Rossmann Fourier autoindexing algorithm in MOSFLM. Acta Crystallogr. Sect. D 55, 1690\u20131695 (1999).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"28601_CR50","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"28601_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/S0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. D 67, 235\u2013242 (2011).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"28601_CR52","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/nar\/27.1.209","volume":"27","author":"MP Lefranc","year":"1999","unstructured":"Lefranc, M. P. et al. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 27, 209\u2013212 (1999).","journal-title":"Nucleic Acids Res."},{"key":"28601_CR53","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"28601_CR54","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. Sect. D 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"28601_CR55","unstructured":"Bricogne, G. et al. BUSTER. https:\/\/www.globalphasing.com\/buster\/wiki\/ (Global Phasing Ltd., Cambridge, United Kingdom, 2017)."},{"key":"28601_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams, C. J. et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 27, 293\u2013315 (2018).","journal-title":"Protein Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28601-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28601-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28601-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:22:36Z","timestamp":1669288956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28601-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28601"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-28601-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"11 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.G.W.A., J.J.I., M.K.H. and S.J.D. are named inventors on patent applications relating to PfRH5 and\/or other malaria vaccines, mAbs, and immunization regimes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"933"}}